Patoloxía Molecular das Doenzas Raras
PatMol-DR
![Foto de Patoloxía Molecular das Doenzas Raras](/img/grupo.png)
![Foto de University of Pisa](/img/noimage_org.png)
University of Pisa
Pisa, ItaliaPublicacións en colaboración con investigadores/as de University of Pisa (8)
2022
-
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up
European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103
-
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520
-
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412
-
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058
2021
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
2020
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392
2018
-
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529
2003
-
The effect of short-term treatment with recombinant human thyroid-stimulating hormones on leydig cell function in men
Thyroid, Vol. 13, Núm. 7, pp. 649-652